Chemokine polymorphisms and lymphoma: A pooled analysis

Paige M. Bracci; Christine F. Skibola; Lucia Conde; Eran Halperin; Tracy Lightfoot; Alex Smith; Randi A. Paynter; Danica R. Skibola; Luz Agana; Eve Roman; Eleanor Kane; John K. Wiencke

doi:10.3109/10428190903518337

Chemokine polymorphisms and lymphoma: A pooled analysis

Paige M. Bracci, Christine F. Skibola, Lucia Conde, Eran Halperin, Tracy Lightfoot, Alex Smith, Randi A. Paynter, Danica R. Skibola, Luz Agana, Eve Roman, Eleanor Kane, John K. Wiencke

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Polymorphisms in chemokine genes have been associated with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL) but are understudied in non-HIV-related NHL. Associations of NHL and NHL subtypes with polymorphisms and haplotypes in CCR5, CCR2, CCL5, CXCL12, and CX ₃CR₁ were explored in a pooled analysis of three casecontrol studies (San Francisco Bay Area, California; United Kingdom; total: cases N1610, controls N1992). Adjusted unconditional logistic regression was used to estimate relative risks among HIV-negative non-Hispanic Caucasians. The CCR5 Δ32 deletion reduced the risk of NHL (odds ratio0.56, 95 confidence interval0.380.83) in men but not women with similar effects observed for diffuse large-cell and follicular lymphoma (FL). NHL risk also was reduced in men with the CCR2/CCR5 haplotype characterized by the CCR5 Δ32 deletion. The CCL5 -403A allele conferred reduced risks of FL and chronic lymphocytic leukemia/small lymphocytic lymphoma. Results should be interpreted conservatively. Continued investigation is warranted to confirm these findings.

Original language	English
Pages (from-to)	497-506
Number of pages	10
Journal	Leukemia and Lymphoma
Volume	51
Issue number	3
DOIs	https://doi.org/10.3109/10428190903518337
State	Published - Mar 2010
Externally published	Yes

Funding

Funders	Funder number
Leukaemia Research of Great Britain
National Institutes of Health
National Cancer Institute	R01CA045614

Keywords

Casecontrol
Chemokines
Genetic
Lymphoma non-Hodgkin
Polymorphism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10428190903518337

Cite this

@article{6c59a37bb78c4809bce49ac80bb7ff4f,

title = "Chemokine polymorphisms and lymphoma: A pooled analysis",

abstract = "Polymorphisms in chemokine genes have been associated with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL) but are understudied in non-HIV-related NHL. Associations of NHL and NHL subtypes with polymorphisms and haplotypes in CCR5, CCR2, CCL5, CXCL12, and CX 3CR1 were explored in a pooled analysis of three casecontrol studies (San Francisco Bay Area, California; United Kingdom; total: cases N1610, controls N1992). Adjusted unconditional logistic regression was used to estimate relative risks among HIV-negative non-Hispanic Caucasians. The CCR5 Δ32 deletion reduced the risk of NHL (odds ratio0.56, 95 confidence interval0.380.83) in men but not women with similar effects observed for diffuse large-cell and follicular lymphoma (FL). NHL risk also was reduced in men with the CCR2/CCR5 haplotype characterized by the CCR5 Δ32 deletion. The CCL5 -403A allele conferred reduced risks of FL and chronic lymphocytic leukemia/small lymphocytic lymphoma. Results should be interpreted conservatively. Continued investigation is warranted to confirm these findings.",

keywords = "Casecontrol, Chemokines, Genetic, Lymphoma non-Hodgkin, Polymorphism",

author = "Bracci, {Paige M.} and Skibola, {Christine F.} and Lucia Conde and Eran Halperin and Tracy Lightfoot and Alex Smith and Paynter, {Randi A.} and Skibola, {Danica R.} and Luz Agana and Eve Roman and Eleanor Kane and Wiencke, {John K.}",

note = "Funding Information: Declaration of interest: This study was funded by grants CA45614, CA104862, and CA122663 and in part by grants CA89745 and CA87014 from the National Cancer Institute, National Institutes of Health (NHL1 and NHL2 studies), and Leukaemia Research of Great Britain (UK study).",

year = "2010",

month = mar,

doi = "10.3109/10428190903518337",

language = "אנגלית",

volume = "51",

pages = "497--506",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Chemokine polymorphisms and lymphoma

T2 - A pooled analysis

AU - Bracci, Paige M.

AU - Skibola, Christine F.

AU - Conde, Lucia

AU - Halperin, Eran

AU - Lightfoot, Tracy

AU - Smith, Alex

AU - Paynter, Randi A.

AU - Skibola, Danica R.

AU - Agana, Luz

AU - Roman, Eve

AU - Kane, Eleanor

AU - Wiencke, John K.

N1 - Funding Information: Declaration of interest: This study was funded by grants CA45614, CA104862, and CA122663 and in part by grants CA89745 and CA87014 from the National Cancer Institute, National Institutes of Health (NHL1 and NHL2 studies), and Leukaemia Research of Great Britain (UK study).

PY - 2010/3

Y1 - 2010/3

N2 - Polymorphisms in chemokine genes have been associated with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL) but are understudied in non-HIV-related NHL. Associations of NHL and NHL subtypes with polymorphisms and haplotypes in CCR5, CCR2, CCL5, CXCL12, and CX 3CR1 were explored in a pooled analysis of three casecontrol studies (San Francisco Bay Area, California; United Kingdom; total: cases N1610, controls N1992). Adjusted unconditional logistic regression was used to estimate relative risks among HIV-negative non-Hispanic Caucasians. The CCR5 Δ32 deletion reduced the risk of NHL (odds ratio0.56, 95 confidence interval0.380.83) in men but not women with similar effects observed for diffuse large-cell and follicular lymphoma (FL). NHL risk also was reduced in men with the CCR2/CCR5 haplotype characterized by the CCR5 Δ32 deletion. The CCL5 -403A allele conferred reduced risks of FL and chronic lymphocytic leukemia/small lymphocytic lymphoma. Results should be interpreted conservatively. Continued investigation is warranted to confirm these findings.

AB - Polymorphisms in chemokine genes have been associated with human immunodeficiency virus (HIV)-related non-Hodgkin lymphoma (NHL) but are understudied in non-HIV-related NHL. Associations of NHL and NHL subtypes with polymorphisms and haplotypes in CCR5, CCR2, CCL5, CXCL12, and CX 3CR1 were explored in a pooled analysis of three casecontrol studies (San Francisco Bay Area, California; United Kingdom; total: cases N1610, controls N1992). Adjusted unconditional logistic regression was used to estimate relative risks among HIV-negative non-Hispanic Caucasians. The CCR5 Δ32 deletion reduced the risk of NHL (odds ratio0.56, 95 confidence interval0.380.83) in men but not women with similar effects observed for diffuse large-cell and follicular lymphoma (FL). NHL risk also was reduced in men with the CCR2/CCR5 haplotype characterized by the CCR5 Δ32 deletion. The CCL5 -403A allele conferred reduced risks of FL and chronic lymphocytic leukemia/small lymphocytic lymphoma. Results should be interpreted conservatively. Continued investigation is warranted to confirm these findings.

KW - Casecontrol

KW - Chemokines

KW - Genetic

KW - Lymphoma non-Hodgkin

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=77249167170&partnerID=8YFLogxK

U2 - 10.3109/10428190903518337

DO - 10.3109/10428190903518337

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:77249167170

SN - 1042-8194

VL - 51

SP - 497

EP - 506

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3

ER -

Chemokine polymorphisms and lymphoma: A pooled analysis

Abstract

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this